On Demand, On Purpose: Fashion Manufacturing That Doesn’t Cost the Earth
Understanding Human Trafficking and Modern Slavery: A Business Imperative with Clint Palermo
PODCAST: Williams Mullen's Benefits Companion - Navigating Fiduciary Responsibilities in a Tide-Turning ESG Era
ESG Essentials: What You Need To Know Now - Episode 18 - The Reshaping of ESG & DEI
Compliance into the Weeds: More Compliance Challenges in the Trump Era
Podcast — UK FinReg Focus Areas in 2025: Sectoral Trends
Environmental and Sustainability Regulations & the New Administration
Podcast - Beyond Compliance: A Deep Dive into Carbon Markets Fraud and the Government's Response
ESG Essentials: What You Need To Know Now - Episode 17 - The Evolution of ESG Enforcement Under the SEC
Navigating ESG: Preparing for Future Regulations (Part Two) — Regulatory Oversight Podcast
Regulatory Uncertainty: Benefits-Related Legal Challenges in a Post-Chevron World — Troutman Pepper Podcast
Navigating ESG: The Growing Importance and Compliance Challenges (Part One) — Regulatory Oversight Podcast
AGG Talks: Cross-Border Business Podcast - Episode 16: The Political and Legal Maze of ESG in the U.S. and Abroad
Episode 326 -- Dottie Schindlinger on Diligent's Report on Board Oversight of Cybersecurity Risks and Performance
Why ESG Matters?
JONES DAY TALKS®: ESG Reporting Rules: The SEC, CSRD, and California– Who's on the Hook?
ESG Masterclass — Legal Risks Hiding in Your DEIB Programming
Leaning in on AI in Compliance Programs
ESG Masterclass — ESG and Impact Investing
ESG Masterclass — Empowering Women and Girls in Sparking Lasting Change
State attorneys general are playing an increasingly prominent role in shaping the antitrust enforcement landscape in the United States. With a combination of expanded authority, increased funding, strategic collaboration, and...more
As we step into a new year, the potential shifts under a second Trump administration loom large. Our 2025 Insights publication analyzes the impacts these changes could have on both U.S. and global business environments,...more
Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed into a significant slowdown during the rest of 2022, with an expectation of continued slowness as we enter...more
As we predicted in the previous edition of this report, 2021 turned out to be a very strong year indeed for US life sciences dealmaking, marked by high transaction values and volumes as the industry continued on its...more
Following a year of healthy activity, M&A deals in the pipeline are set to sustain leveraged finance issuance in the pharmaceutical, medical and biotech sector in the months ahead - Lender appetite for exposure to the...more
Despite political and economic uncertainties, markets and deal activity were resilient in 2019, and strong fundamentals remain in place heading into 2020. Companies continue to face a challenging litigation and enforcement...more